These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23144443)

  • 1. Disease volumes as a marker for patient response in malignant pleural mesothelioma.
    Labby ZE; Nowak AK; Dignam JJ; Straus C; Kindler HL; Armato SG
    Ann Oncol; 2013 Apr; 24(4):999-1005. PubMed ID: 23144443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE; Fahmy ES
    Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.
    Zilembo N; Vitali M; Pietrantonio F; Platania M; Del Vecchio M; Bajetta E
    Tumori; 2010; 96(6):1031-4. PubMed ID: 21388071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
    Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
    Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
    Labby ZE; Armato SG; Dignam JJ; Straus C; Kindler HL; Nowak AK
    J Thorac Oncol; 2013 Apr; 8(4):478-86. PubMed ID: 23486268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Ceresoli GL; Garassino I; De Vincenzo F; Cavina R; Campagnoli E; Cappuzzo F; Salamina S; Soto Parra HJ; Santoro A
    Cancer; 2008 Apr; 112(7):1555-61. PubMed ID: 18286536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciduoid pleural mesothelioma in an adolescent.
    Arango-Tomás E; Algar-Algar FJ; Salvatierra Velázquez A
    Arch Bronconeumol; 2013 May; 49(5):218-9. PubMed ID: 23265622
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
    Berardi R; Caramanti M; Fiordoliva I; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Castagnani M; Rovinelli F; Onofri A; Cascinu S
    Support Care Cancer; 2015 Mar; 23(3):621-6. PubMed ID: 25142706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
    Agatsuma T; Koizumi T; Yasuo M; Urushihata K; Tsushima K; Yamamoto H; Hanaoka M; Fukushima M; Honda T; Kubo K
    Jpn J Clin Oncol; 2010 Dec; 40(12):1180-3. PubMed ID: 20603247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
    Cihan YB; Ozturk A; Mutlu H
    Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
    Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
    Mutlu H; Buyukcelik A; Karaca H; Aksahin A; Berk V; Aslan T; Erden A; Akca Z; Ozkan M
    Asian Pac J Cancer Prev; 2013; 14(6):3887-9. PubMed ID: 23886202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.
    Hooper CE; Lyburn ID; Searle J; Darby M; Hall T; Hall D; Morley A; White P; Rahman NM; De Winton E; Clive A; Masani V; Arnold DT; Dangoor A; Guglani S; Jankowska P; Lowndes SA; Harvey JE; Braybrooke JP; Maskell NA
    Br J Cancer; 2015 Mar; 112(7):1175-82. PubMed ID: 25756396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
    Kucukoner M; Ali Kaplan M; Inal A; Urakci Z; Abakay O; Cetin Tanrikulu A; Abakay A; Selim Sen H; Turkcu G; Senyigit A; Buyukbayram H; Isikdogan A
    J BUON; 2014; 19(1):164-70. PubMed ID: 24659659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel combinations using pemetrexed in malignant mesothelioma.
    Gadgeel SM; Pass HI
    Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S61-6. PubMed ID: 15117427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
    Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
    Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
    Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.